Simranjit SINGH


Simranjit is an Operating Partner at Keensight.

Simranjit has more than 18 years of senior management experience in Asia Pacific working with biopharma, diagnostics and medical device companies for their R&D, business expansion, and growth strategies for the region.

Simran is currently the CEO of Guardant Health AMEA (GH AMEA), a precision oncology company which is a pioneer in comprehensive genomic profiling (liquid biopsies). The company has a vast portfolio of diagnostic tests across the continuum of cancer from late-stage cancer to recurrence monitoring to early cancer detection. It has a presence across 41 countries in Asia, Middle East & Africa. Simran also sits on the oversight committee of the National Health Innovation Centre under the auspices of MOH Singapore & the Evaluation committee for the Diagnostics Development Hub under the Agency for Science, Technology & Research

Prior to Guardant Health, Simran was the Vice President of the Global medical devices & diagnostics division & Head of Strategic Planning Asia for IQVIA, a Global CRO where he was instrumental to drive IQVIA’s growth strategy for Asia Pacific and accelerate revenue growth.